Best Researcher Award

Silvia Brandalise – Hospital Boldrini

Silvia Brandalise is a Brazilian medical researcher affiliated with Hospital Boldrini, an institution recognized for pediatric oncology and hematology research. Her scholarly profile demonstrates substantial academic productivity, international collaboration, and long-term contributions to childhood cancer studies. Through clinical investigations and translational research, she has contributed to the advancement of pediatric healthcare and evidence-based medical practice.[1]

Abstract

This article summarizes the academic profile of Silvia Brandalise and evaluates her suitability for recognition through the Best Researcher Award. Her scientific record reflects sustained engagement in pediatric oncology, leukemia research, and clinical medicine. The combination of scholarly productivity, citation performance, and international collaboration highlights a significant contribution to healthcare research and patient-centered scientific advancement.[1]

Keywords

Pediatric Oncology, Childhood Leukemia, Clinical Research, Cancer Genomics, Translational Medicine, Biomarker Discovery, Medical Sciences, Oncology Research, Pediatric Tumors, Evidence-Based Medicine.

Introduction

Medical research plays a critical role in improving treatment outcomes and expanding scientific understanding of complex diseases. Silvia Brandalise has contributed to this objective through extensive involvement in pediatric cancer investigations and collaborative studies. Her work spans clinical applications, molecular research, and healthcare innovation, supporting advances in diagnosis, prognosis, and treatment strategies for young patients.[2]

Research Profile

According to Scopus metrics, Brandalise has produced more than one hundred scholarly publications and accumulated thousands of citations from the global research community. Her h-index indicates a consistent pattern of influence across multiple studies. The breadth of collaborations and multidisciplinary participation further demonstrates her active role in contemporary medical research and scientific leadership.[1]

Research Contributions

Her research contributions include investigations into acute lymphoblastic leukemia, pediatric adrenocortical tumors, cancer biomarkers, molecular oncology, and treatment optimization. These studies contribute valuable clinical evidence and biological insights that support improved patient management. Several collaborative publications also address prognostic markers and therapeutic approaches relevant to pediatric oncology practice worldwide.[3]

Publications

Recent publications associated with Brandalise include studies on leukemia drug profiling, pediatric medulloblastoma biomarkers, adrenocortical tumor biology, and chemotherapy-related adverse events. These articles demonstrate continued engagement with clinically relevant research questions and illustrate a commitment to translating scientific findings into practical healthcare applications. The publication record reflects both depth and diversity within the field of medicine.[4]

Research Impact

The impact of Brandalise’s work is reflected in citation activity, collaborative networks, and continued relevance within oncology research. Her studies have supported scientific discussions on disease mechanisms, prognostic assessment, and treatment outcomes. Such influence indicates that her contributions extend beyond publication volume and contribute meaningfully to ongoing academic and clinical development.[1]

Award Suitability

Silvia Brandalise demonstrates several characteristics commonly associated with academic recognition, including sustained research productivity, measurable scholarly influence, and contributions to healthcare advancement. Her publication record and research impact support consideration for the Best Researcher Award. These achievements align with the objectives of recognizing excellence, innovation, and scientific contribution within the global research community.[5]

Conclusion

The academic profile of Silvia Brandalise reflects a distinguished career in medicine and pediatric oncology research. Through extensive publications, international collaborations, and impactful clinical studies, she has contributed to scientific knowledge and healthcare improvement. Her achievements provide a strong foundation for recognition through academic and professional award programs.[1]

External Links

• Scopus Author Profile
• Award Website

References

1. Elsevier. (2026). Scopus author details: Silvia Regina Brandalise, Author ID 6601905996. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=6601905996
2. Mariano, S. S., Assis, L. H. D. P., Corrêa, J. R., et al. (2026). ELDA: real-time functional drug profiling in acute lymphoblastic leukemia. Frontiers in Oncology.
   https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1685447/full
3. Riedmeier, M., Antonini, S. R. R., Brandalise, S. R., et al. (2024). International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors. European Journal of Endocrinology.
   https://pubmed.ncbi.nlm.nih.gov/38552173/
4. Correa, C. A. P., Chagas, P. S., Baroni, M., et al. (2025). miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma. Cerebellum.
   https://link.springer.com/article/10.1007/s12311-025-01812-3
5. Silva-Rodrigues, F. M., Hinds, P. S., Scrideli, C. A., et al. (2025). Pain as an Adverse Event During Chemotherapy in Children with Acute Lymphoblastic Leukemia. Cancer Control.
   https://pubmed.ncbi.nlm.nih.gov/40396443/